Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-05-24
2011-12-06
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S093100, C424S093200, C424S184100, C424S200100, C424S203100, C424S234100, C536S023100, C536S023700
Reexamination Certificate
active
08071113
ABSTRACT:
The invention relates toSalmonella typhiTy21a comprising core-linkedShigella dysenteriaeserotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encodingShigella dysenteriaeserotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.
REFERENCES:
Wang, L. et al. Infection and Immunity, vol. 69, No. 11, pp. 6923-6930, Nov. 2001.
Klena, J.D., et al. Journal of Bacteriology, vol. 174, No. 22, pp. 7297-7307, Nov. 1992.
Klena, J.D., et al. Molecular Microbiology, vol. 9, No. 2, pp. 393-402, 1993.
Baron, L.S. et al. (1987) “Introduction ofShigella flexneri2a type and group antigen genes into oral typhoid vaccine strainSalmonella typhiTy21a.”Infect. Immun. 55:2797-2801.
Black R.E. et al. (1987) “Prevention of shigellosis by aSalmonella typhi-Shigella sonneibivalent vaccine.”J. Infect. Dis. 155:1260-5.
Churchward G. et al. (1984) “pSC101-derived plasmid which shows no sequence homology to other commonly used cloning vectors.”Gene31:165-71.
Database EMBL (1992) Database accession no. L07293, Dec. 3, 1992.
Database EMBL (1992) Database accession No. M96064, Jun. 30, 1992.
Database EMBL (1995) Database accession No. S73325, May 26, 1995.
Database EMBL (2001) Database accession No. AF402313, Nov. 5, 2001.
Database EMBL (2002) Database accession No. AF529080, Oct. 29, 2002.
Database UniProt (1995) Database accession No. Q03583, Feb. 1, 1995.
Database UniProt (1995) Database accession No. Q03584, Feb. 1, 1995.
Database UniProt (1996) Database accession No. Q03581, Nov. 1, 1996.
Database UniProt (1996) Database accession No. Q03582, Nov. 1, 1996.
Database UniProt (1996) Database accession No. Q53982, Nov. 1, 1996.
Database UniProt (2001) Database accession No. Q93CU2, Dec. 1, 2001.
Database UniProt (2001) Database accession No. Q93CV2, Dec. 1, 2001.
Database UniProt (2001) Database accession No. Q93CV3, Dec. 1, 2001.
Database UniProt (2002) Database accession No. AAU09677, Feb. 27, 2002.
Datsenko, K.A. et al. (2000) “One-step inactivation of chromosomal genes inEscherichia coliK-12 using PCR products.”PNAS USA97:6640-5.
Dmitriev, B.A. et al. (1976) “Somatic antigens ofShigella. Structural investigation on the O-specific polysaccharide chain ofShigella dysenteriaetype 1 lipopolysaccharide.”Eur. J. Biochem. 66:559-566.
Dupont, H.L. et al. (1989) “Inoculum size in shigellosis and implications for expected mode of transmission.”J. Infect. Dis. 159:1126-1128.
Dworkin, M.S. et al. (2001) “Reactive arthritis and Reiter's syndrome following an outbreak of gastroenteritis caused bySalmonella enteritidis.” Clin. Infect. Dis. 33:1010-4.
Engels, E.A. et al. (1998) “Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity.”BMJ316:110-6.
Falt, I.C. et al. (1995) “Expression ofShigella dysenteriaeserotype 1 O-antigenic polysaccharide byShigella flexneriaroD vaccine candidates and differentS. flexneriserotypes.”J. Bacteriol. 177:5310-5315.
Falt, I.C. et al. (1996) “Construction of recombinant aroASalmonellaestably producing theShigella dysenteriaeserotype 1 O-antigen and structural characterization of theSalmonella/Shigellahybrid LPS.”Microb. Pathog. 20:11-30.
Favre, D. et al. (1996) “Development ofShigella sonneilive oral vaccines based on defined rtbInabadeletion mutants ofVibrio choleraeexpressing theShigellaserotype D O polysaccharide.”Infect. Immun. 64:576-584.
Feng, L. et al. (2007) “Structural and genetic evidence that theEscherichia coliO148 O antigen is the precursor of theShigella dysenteriaetype 1 O antigen and identification of a glucosyltransferase gene.”Microbiology153(Pt 1):139-47.
Fernandez, M.I. et al. (2003) “A newborn mouse model for the study of intestinal pathogenesis of shigellosis.”Cell Microbiol. 5:481-91.
Formal, S.B. et al. (1981) “Construction of a potential bivalent vaccine strain: introduction ofShigella sonneiform I antigen genes into thegalE Salmonella typhiTy21a typhoid vaccine strain.”Infect. Immun. 34:746-750.
Franco, A.V. et al. (1996) “A Wzz (Cld) protein determines the chain length of K lipopolysaccharide inEscherichia coliO8 and O9 strains.”J. Bacteriol. 178:1903-7.
Gentry, MK. et al. (1980) “Quantitative microtiter cytotoxicity assay forShigellatoxin.”J. Clin. Microbiol. 12:361-6.
Gentschev, I. et al. (2007) “Vivotif®—a ‘magic shield’ for protection against typhoid fever and delivery of heterologous antigens.”Chemotherapy53:177-80.
Germanier, R. et al. (1971) “Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity ofgalE mutants ofSalmonella typhimurium.” Infect. Immun. 4:663-73.
Germanier, R. et al. (1975) “Isolation and characterization ofGalE mutant Ty 21a ofSalmonella typhi: a candidate strain for a live, oral typhoid vaccine.”J. Infect. Dis. 131:553-8.
Hale, T.L. et al. (1984) “Expression of lipopolysaccharide O antigen inEscherichia coliK-12 hybrids containing plasmid and chromosomal genes fromShigella dysenteriae1.”Infect. Immun. 46:470-475.
Hartman, A.B. et al. (1991) “Molecular analysis of variant plasmid forms of a bivalentSalmonella typhi-Shigella sonneivaccine strain.”J. Clin. Microbiol. 29:27-32.
Herrington, D.A. et al. (1990) “Studies in volunteers to evaluate candidateShigellavaccines: further experience with a bivalentSalmonella typhi-Shigella sonneivaccine and protection conferred by previousShigella sonneidisease.”Vaccine8:353-357.
Hoare, A. et al. (2006) “The outer core lipopolysaccharide ofSalmonella entericaserovar Typhi is required for bacterial entry into epithelial cells.”Infect. Immun. 74:1555-64.
International Preliminary Examination report on Patentability from the PCT Application PCT/US2005/018198.
Ivanoff, B. et al. (1994) “Vaccination against typhoid fever: present status.”Bull. World Health Organ. 72:957-71.
Johnson, J.A. et al. (1994) “Vibrio cholerae O139 synonym Bengal is closely related to Vibrio cholerae El Tor but has important differences.”Infect. Immun. 62:2108-10.
Klee, S.R. et al. (1997) “Construction and characterization of a live attenuated vaccine candidate againstShigella dysenteriaetype 1.”Infect Immun. 65:2112-2118.
Klee, S.R. et al. (1997) “Influence of differentrolgene products on the chain length ofShigella dysenteriaetype 1 lipopolysaccharide O antigen expressed byShigella flexnericarrier strains.”J. Bacteriol. 179:2421-2425.
Klena, J.D. et al. (1992) “Role ofEscherichia coliK-12rfaGenes and therfpGene ofShigella dysenteriae1 in Generation of Lipopolysaccharide Core Heterogeneity and Attachment of O Antigen.”J. Bacteriol. 174:7297-7307.
Klena, J.D. et al. (1993) “Function of therfbgene cluster and therfegene in the synthesis of O antigen byShigella dysenteriae1.”Mol. Microbiol. 9:393-402.
Kotloff, K.L. et al. (1999) “Global burden ofShigellainfections: implications for vaccine development and implementation of control strategies.”Bull. World Health Organ. 77:651-666.
Levine, M.M. (1982) “Bacillary dysentery: mechanisms and treatment.”Med. Clin. North. Am. 66:623-638.
Levine, M.M. et al. (1999) “Duration of efficacy of Ty21a, attenuatedSalmonella typhilive oral vaccine.”Vaccine17 Suppl 2:S22-7.
Maurelli, A.T. et al. (1998) “Shigellainfection as observed in the experimentally inoculated domestic pig,Sus scrofa domestica.” Microb. Pathog. 25:189-96.
Kopecko Dennis J.
Xu De-Qi
Swanson & Bratschun LLC
Swartz Rodney P.
The United States of America as represented by the Department of
LandOfFree
Live, oral vaccine for protection against Shigella... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live, oral vaccine for protection against Shigella..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live, oral vaccine for protection against Shigella... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256480